Structured evidence table for Beta Glucan Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Beta Glucan Gut Health Randomized Trial | By interacting with innate pattern recognition receptors (PRRs), including Dectin-1 and Toll-like receptors (TLRs), expressed on gut-associated lymphoid tissue (GALT) and immune cells, β-1,3-glucans regulate both innate and adaptive immune responses [,]. | 4 | Samiksha Fnu (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation |
| Beta Glucan Gut Health Randomized Trial | Table 2 A summary of β-glucans derived from different fungal sources and their associated therapeutic properties is provided in. | 4 | Samiksha Fnu (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation |
| Beta Glucan Gut Health Randomized Trial | Although multiple receptor systems are involved, the overall framework is conserved and relies on the detection of pathogen-associated molecular patterns (PAMPs) by PRR families, including Dectin-1, TLRs, complement receptor 3 (CR3), lactosylceramide (LacCer), and scavenger receptors (SRs). | 4 | Samiksha Fnu (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation |
| Beta Glucan Gut Health Randomized Trial | 1 2 2 Glucans are polysaccharides composed entirely of glucose monomers and are generally classified into three structural categories: α-glucans, β-glucans, and mixed α, β-glucans [,]. | 4 | Samiksha Fnu (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation |
| Beta Glucan Gut Health Randomized Trial | 1 2 3 4 5 6 7 8 9 10 11 Obesity has emerged as a major global public health challenge and is closely associated with a range of metabolic complications, including dyslipidemia, insulin resistance and metabolic dysfunction-associated fatty liver disease (MAFLD) [,,,]. | 4 | Guo Zongzhen (2026) | Combined Oat β-Glucan and Soy Protein Isolate Reprogram Gut Microbiota and Improve Metabolic Dysfunction in Diet-Induced Obesity |
| Beta Glucan Gut Health Randomized Trial | Consistent with these regulatory effects, higher intake of whole grain has been shown to improve long-term weight management and reduce cardiometabolic risk profiles, as supported by rigorous prospective cohort studies and systematic evaluations of dietary patterns [,,]. | 4 | Guo Zongzhen (2026) | Combined Oat β-Glucan and Soy Protein Isolate Reprogram Gut Microbiota and Improve Metabolic Dysfunction in Diet-Induced Obesity |
| Beta Glucan Gut Health Randomized Trial | Mechanistic studies in high-fat diet (HFD)-fed mice also indicate that β-glucan may ameliorate insulin resistance and intestinal barrier dysfunction, providing a plausible link to improved glucose homeostasis []. | 4 | Guo Zongzhen (2026) | Combined Oat β-Glucan and Soy Protein Isolate Reprogram Gut Microbiota and Improve Metabolic Dysfunction in Diet-Induced Obesity |
| Beta Glucan Gut Health Randomized Trial | Although pharmacological and surgical interventions offer clinical benefits for specific populations with obesity, scalable and sustainable population-level prevention largely depends on dietary strategies that enhance metabolic health. | 4 | Guo Zongzhen (2026) | Combined Oat β-Glucan and Soy Protein Isolate Reprogram Gut Microbiota and Improve Metabolic Dysfunction in Diet-Induced Obesity |
Source documents